Companies › Crinetics Pharmaceuticals
4 active drug programs in 6 registered trials: 2 Phase 3, 2 Phase 2, 2 Phase 1; Oncology, Genitourinary, Metabolic and endocrine; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Atumelnant Melanocortin 2 receptor (MC2R/ACTH receptor) antagonist | MC2R | Phase 3 | Congenital Adrenal Hyperplasia | May 2027 |
| Paltusotine Somatostatin receptor 2 agonist | SSTR2 | Phase 3 | Carcinoid Syndrome | Aug 2027 |
| CRN09682 SST2-targeting therapy for neuroendocrine and solid tumors | – | Phase 1 | SST2-positive Neuroendocrine Neoplasms | Aug 2027 |
| CRN04894 ACTH receptor antagonist | ACTHLY | Phase 1 | Cushing Syndrome | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05804669 | CRN04894 | Phase 1 | Cushing Syndrome | Metabolic and endocrine | Aug 2026 |
| NCT07144163 | Atumelnant | Phase 3 | Congenital Adrenal Hyperplasia | Genitourinary | May 2027 |
| NCT07129252 | CRN09682 | Phase 1 | SST2-positive Neuroendocrine Neoplasms | Oncology | Aug 2027 |
| NCT07087054 | Paltusotine | Phase 3 | Carcinoid Syndrome | Oncology | Aug 2027 |
| NCT06712823 | Atumelnant | Phase 2 | Congenital Adrenal Hyperplasia | Genitourinary | Jul 2029 |
| NCT07159841 | Atumelnant | Phase 2 | Congenital Adrenal Hyperplasia | Genitourinary | Mar 2030 |
Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Debiopharm International RayzeBio Biocity Biopharmaceutics Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Jiangsu Alphamab Biopharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.